azoxymethane has been researched along with Cirrhosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Donthi, D; Hong, H; Lertpiriyapong, K; Marie, MA; Sanderlin, EJ; Satturwar, S; Yang, LV | 1 |
| Ahmad, D; Cheng, K; Jadeja, RN; Khurana, S; Rachakonda, V; Raufman, JP; Shah, N; Twaddell, WS; Urrunaga, NH | 1 |
2 other study(ies) available for azoxymethane and Cirrhosis
| Article | Year |
|---|---|
GPR65 (TDAG8) inhibits intestinal inflammation and colitis-associated colorectal cancer development in experimental mouse models.
Topics: Animals; Azoxymethane; Colitis; Colitis-Associated Neoplasms; Colon; Dextran Sulfate; Disease Models, Animal; Fibrosis; Gene Expression Regulation; Humans; Inflammation; Inflammatory Bowel Diseases; Leukocytes; Mice; Mice, Knockout; Receptors, G-Protein-Coupled; Severity of Illness Index | 2022 |
M1 Muscarinic Receptor Deficiency Attenuates Azoxymethane-Induced Chronic Liver Injury in Mice.
Topics: Acute Disease; Animals; Apoptosis; Azoxymethane; Bile Ducts; Cell Survival; Disease Models, Animal; Fibrosis; Hepatic Stellate Cells; Hepatocytes; Hyperplasia; Liver Diseases; Matrix Metalloproteinases; Mice; Mice, Knockout; Oxidative Stress; Receptor, Muscarinic M1; Tissue Inhibitor of Metalloproteinases | 2015 |